Literature DB >> 7507512

Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine.

C A Dahinden1, T Geiser, T Brunner, V von Tscharner, D Caput, P Ferrara, A Minty, M Baggiolini.   

Abstract

CC chemokines constitute a novel class of cytokines that attract and activate monocytes and lymphocytes, as well as basophil and eosinophil leukocytes, with distinct target cell profiles, and are believed to be involved in the regulation of different types of inflammation. The action of the recently identified monocyte chemotactic protein 3 (MCP-3) on human basophil and eosinophil function was studied and compared with that of other CC chemokines. In basophils, MCP-3, MCP-1, RANTES, and macrophage inflammatory protein (MIP)-1 alpha all induced cytosolic-free calcium concentration ([Ca2+]i) changes and, with different efficacies, chemotaxis (RANTES = MCP-3 >> MCP-1 > MIP-1 alpha), histamine release (MCP-1 = MCP-3 >> RANTES > MIP-1 alpha), and leukotriene C4 formation, after IL-3 pretreatment (MCP-1 = MCP-3 >> RANTES > MIP-1 alpha). Thus, MCP-3 was as effective as MCP-1 as an inducer of mediator release, and as effective as RANTES as a stimulus of basophil migration. In contrast to MCP-1, MCP-3 was also a stimulus for eosinophils, and induced [Ca2+]i changes and chemotaxis as effectively as RANTES, which is the most potent chemotactic cytokine for these cells. Desensitization of the transient changes in [Ca2+]i was used to assess receptor usage. In basophils, stimulation with MCP-3 prevented responsiveness to MCP-1 and RANTES, but not to MIP-1 alpha. No single CC chemokine (except for MCP-3 itself) affected the response to MCP-3, however, which was prevented only when the cells were prestimulated with both MCP-1 and RANTES. In eosinophils, by contrast, cross-desensitization between RANTES and MCP-3 was obtained. RANTES and to a lesser extent MCP-3 also desensitized eosinophils toward MIP-1 alpha. The desensitization data suggest the existence of three chemokine receptors: (a) a MCP-1 receptor expressed on basophils but not eosinophils that is activated by MCP-1 and MCP-3; (b) a RANTES receptor in basophils and eosinophils that is activated by RANTES and MCP-3; and (c) a MIP-1 alpha receptor that is activated by MIP-1 alpha, RANTES and, more weakly, by MCP-3. This study shows that MCP-3 combines the properties of RANTES, a powerful chemoattractant, and MCP-1, a highly effective stimulus of mediator release, and thus has a particularly broad range of activities toward both human basophil and eosinophil leukocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507512      PMCID: PMC2191381          DOI: 10.1084/jem.179.2.751

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils.

Authors:  S C Bischoff; C A Dahinden
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

2.  RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors.

Authors:  S C Bischoff; M Krieger; T Brunner; A Rot; V von Tscharner; M Baggiolini; C A Dahinden
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

3.  Activation of human basophils through the IL-8 receptor.

Authors:  M Krieger; T Brunner; S C Bischoff; V von Tscharner; A Walz; B Moser; M Baggiolini; C A Dahinden
Journal:  J Immunol       Date:  1992-10-15       Impact factor: 5.422

4.  RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils.

Authors:  P Kuna; S R Reddigari; T J Schall; D Rucinski; M Y Viksman; A P Kaplan
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

5.  Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor.

Authors:  K Neote; D DiGregorio; J Y Mak; R Horuk; T J Schall
Journal:  Cell       Date:  1993-02-12       Impact factor: 41.582

6.  Immunoglobulin E plus antigen challenge induces a novel intercrine/chemokine in mouse mast cells.

Authors:  P A Kulmburg; N E Huber; B J Scheer; M Wrann; T Baumruker
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

7.  Monocyte chemotactic protein 1 is a potent activator of human basophils.

Authors:  S C Bischoff; M Krieger; T Brunner; C A Dahinden
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

8.  RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes.

Authors:  A Rot; M Krieger; T Brunner; S C Bischoff; T J Schall; C A Dahinden
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

9.  Macrophage inflammatory protein-1 alpha activates basophils and mast cells.

Authors:  R Alam; P A Forsythe; S Stafford; M A Lett-Brown; J A Grant
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

10.  Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils.

Authors:  Y Kameyoshi; A Dörschner; A I Mallet; E Christophers; J M Schröder
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

View more
  70 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Chemokines in the limbal form of vernal keratoconjunctivitis.

Authors:  A M Abu El-Asrar; S Struyf; S A Al-Kharashi; L Missotten; J Van Damme; K Geboes
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 3.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

4.  Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.

Authors:  K Yanaba; K Komura; M Kodera; T Matsushita; M Hasegawa; K Takehara; S Sato
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 5.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

Review 6.  Inflammation in traumatic brain injury: role of cytokines and chemokines.

Authors:  R S Ghirnikar; Y L Lee; L F Eng
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 7.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

8.  Dynamic interplay of transcriptional machinery and chromatin regulates "late" expression of the chemokine RANTES in T lymphocytes.

Authors:  Yong-Tae Ahn; Boli Huang; Lisa McPherson; Carol Clayberger; Alan M Krensky
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

9.  Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils.

Authors:  C Weber; J Kitayama; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Pathogenic role of mast cells in experimental eosinophilic esophagitis.

Authors:  Rituraj Niranjan; Parm Mavi; Madhavi Rayapudi; Scott Dynda; Anil Mishra
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-04-18       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.